Mitchell Mutz
Directeur Financier/CFO chez EpiBiologics, Inc.
Profil
Mitchell Mutz, PhD, is an Entrepreneur Partner of Vivo Capital.
He is a successful biotech serial entrepreneur, venture investor, and inventor with over 20 years experience in starting and investing in biotechnology companies.
Mitchell was previously Senior Investment Director of the Roche Venture Fund where he led new investments in and served on the boards of Pandion Therapeutics (acquired by Merck), Good Therapeutics, Jasper Therapeutics, EnLiven Therapeutics (observer) and Kumquat Biosciences (observer).
Previously, Mitchell was a co-founder, president, chief scientific officer, and board member of Amplyx Pharmaceuticals, Inc., a biotherapeutics company, acquired by Pfizer.
Mitchell was also on the founding team and the Principal Scientist of Labcyte, a tools company he helped grow from inception and was later acquired by Beckman-Coulter, Inc.
Mitchell earned a Ph.D.
in Chemistry from the University of Rochester, a Diploma in Orchestral Studies from the University of London, and a B.A.
in Chemistry with high honors from Oberlin College.
Postes actifs de Mitchell Mutz
| Sociétés | Poste | Début |
|---|---|---|
Pandion Operations, Inc.
 Pandion Operations, Inc. Miscellaneous Commercial ServicesCommercial Services Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
| Codon Capital | Private Equity Investor | 10/08/2020 |
Vivo Capital LLC
 Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01/07/2021 |
Bonum Therapeutics, Inc.
 Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
EpiBiologics, Inc.
 EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Directeur Financier/CFO | - |
Anciens postes connus de Mitchell Mutz
| Sociétés | Poste | Fin |
|---|---|---|
| PANDION THERAPEUTICS, INC. | Directeur/Membre du Conseil | 02/12/2020 |
Roche Ventures
 Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Private Equity Investor | 01/08/2020 |
| Codon Capital | Corporate Officer/Principal | 01/01/2017 |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Fondateur | 01/07/2016 |
| ░░░░░░ ░░ ░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Mitchell Mutz
| Rochester Christian University | Doctorate Degree |
| Oberlin College | Undergraduate Degree |
| Goldsmiths College University of London | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | Finance |
BlueLight Therapeutics, Inc.
 BlueLight Therapeutics, Inc. BiotechnologyHealth Technology BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA. | Health Technology |
Purigen Biosystems, Inc.
 Purigen Biosystems, Inc. BiotechnologyHealth Technology Purigen Biosystems, Inc. engages in extracting, enriching and quantifying DNA and RNA from biological samples. The company was founded in 2012 by Amy Hiddessen, Klint Rose and Juan Santiago and is headquartered in Pleasanton, CA. | Health Technology |
Labcyte, Inc.
 Labcyte, Inc. Medical/Nursing ServicesHealth Services Labcyte, Inc. operates as a biotechnology tools company that manufactures and markets echo liquid handling systems. It offers liquid handling, automation and consumables. The company was founded by Richard Nathan Ellson and Mark D. Fischer-Colbrie and A. Mark Bramwell in October 2003 and is headquartered in Sunnyvale, CA. | Health Services |
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Finance |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Health Technology |
Pandion Operations, Inc.
Pandion Operations, Inc. Miscellaneous Commercial ServicesCommercial Services Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA. | Commercial Services |
Good Therapeutics, Inc.
 Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA. | Health Technology |
Jasper Tx Corp.
 Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | Health Technology |
Pandion Therapeutics, Inc.
 Pandion Therapeutics, Inc. BiotechnologyHealth Technology Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA. | Health Technology |
| Codon Capital | |
Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | Commercial Services |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Commercial Services |